S-1: Coeptis Therapeutics Registers Shares for Resale, Outlines Growth Strategy

Coeptis Therapeutics files an S-1 registration statement for the resale of up to 3,919,349 shares of common stock by selling stockholders, including shares issuable under a Standby Equity Purchase Agreement with Yorkville.

Summary

• Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company focused on cell therapy technologies, has filed a registration statement for the resale of up to 3,919,349 shares of its common stock.
• The shares include those held by selling stockholders and those issuable to YA II PN, LTD. (Yorkville) under a Standby Equity Purchase Agreement (SEPA).
• The company may receive up to $20 million in gross proceeds from sales of common stock to Yorkville under the SEPA.
• Coeptis will not receive any proceeds from the sale of shares by the selling stockholders.
• The company implemented a 1-for-20 reverse stock split on December 30, 2024.
• Coeptis is pursuing a four-pronged growth strategy: portfolio optimization, strategic partnerships, business development, and sales and marketing.
• The company's product pipeline includes CD38-GEAR-NK, CD38-Diagnostic, and the SNAP-CAR platform.
• Coeptis acquired an AI-powered marketing software and advanced robotic process automation (RPA) platform in December 2024.
• The company is an emerging growth company and is subject to reduced public company reporting requirements.
• As of January 8, 2025, the last reported sales price of Coeptis' Common Stock was $5.91 per share.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the potential for future funding through the SEPA and the company's growth strategy, there are also significant risks and uncertainties, including a history of losses and doubts about the company's ability to continue as a going concern.

Positives

• The Standby Equity Purchase Agreement (SEPA) with Yorkville provides a potential source of funding up to $20 million.
• The company's four-pronged growth strategy aims to maximize success and diversify risk.
• The acquisition of an AI-powered marketing software and advanced robotic process automation (RPA) platform could provide new revenue streams.
• The company's product pipeline includes CD38-GEAR-NK, CD38-Diagnostic, and the SNAP-CAR platform, targeting significant market opportunities.
• The company has an exclusive license agreement with the University of Pittsburgh for the SNAP-CAR technology.

Negatives

• The company will not receive any proceeds from the sale of shares by the selling stockholders.
• The company has a history of losses and expects to incur losses in the future.
• The company is currently out of compliance with the listing maintenance requirements of the Nasdaq Capital Market, and if it doesn't regain compliance by January 15, 2025 it will likely be delisted.
• There is a substantial doubt about the company's ability to continue as a going concern.

Risks

• The company may not be able to successfully implement its growth strategy.
• The company may not be able to obtain and maintain third-party relationships necessary to develop, commercialize, and manufacture product candidates.
• The drug development and approval process is uncertain, time-consuming, and expensive.
• Competition in the biotechnology and pharmaceutical industries may result in competing products and lower revenues.
• Healthcare reform measures could adversely affect the company's business.
• Protecting and defending against intellectual property claims may have a material adverse effect on the company's business.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.

Future Outlook

The company expects to continue generating operating losses and experiencing negative cash flow from operations at least through the end of 2024 or longer and will require both short-term financing for operations and long-term capital to fund its expected growth.

Industry Context

The document highlights Coeptis' focus on cell therapy technologies, which aligns with the growing interest and investment in the biotechnology and pharmaceutical industries, particularly in areas like oncology and autoimmune diseases. The company's strategic partnerships and collaborations are also common in the industry, as they allow companies to leverage expertise and resources to develop and commercialize new therapies.

Comparison to Industry Standards

• The document mentions the CAR T-cell therapy market, citing Polaris Market Research's expectation that it will reach $20.56 billion by 2029, representing a CAGR of 31.6% from 2022 to 2029.
• This growth rate is comparable to other projections for the CAR T-cell therapy market, which is driven by the increasing adoption of these therapies for hematologic malignancies and the potential for expansion into solid tumors.
• Companies like Novartis (Kymriah) and Gilead Sciences (Yescarta) are key players in the CAR T-cell therapy market, and Coeptis' SNAP-CAR platform aims to compete with these existing therapies by offering a more programmable and potentially safer approach.

Related Party Transactions

• On April 17, 2024, the Company entered into an unsecured note agreement with a related party in the principal amount of $500,000 together with interest at 10 %, with a maturity date of September 30, 2024.
• The agreement is between the Company and an investment fund where the manager is a member of the Companys board of directors.
• On June 3, 2024, the Company and the related party agreed to convert the note agreement in full, both principal and interest, to equity in connection with the Companys Series A Preferred Stock offering.

Stakeholder Impact

• Shareholders may experience dilution from the issuance of shares under the SEPA.
• The company's ability to develop and commercialize new therapies could benefit patients.
• Employees' jobs may be affected by the company's financial performance and strategic decisions.
• The company's relationships with suppliers and partners may be impacted by its ability to secure funding and execute its growth strategy.

Next Steps

• The selling stockholders may offer the shares from time to time on terms to be determined at the time of sale.
• The company expects that proceeds received from sales under the SEPA will be used primarily for working capital and general corporate purposes.
• The Company intends to focus on how to utilize the NexGenAI Affiliates Network platform as a source of revenue, with the goal of assisting itself and others to optimize marketing, operations and customer engagements and drive measurable results for users of the platform.
• The Company is continuing its development focus on both GEAR and SNAP-CAR, and will be considering prospective strategic partners for such development.
• Vy-Gen is actively engaged in the research and development of GEAR-NK, and through the joint steering committee, we are assessing market opportunities, intellectual property protection and potential regulatory strategy. No human clinical trials have been conducted for GEAR-NK but are planned for 2025.

Key Dates

Keywords

Coeptis Therapeutics, registration statement, common stock, resale, SEPA, Yorkville, biopharmaceutical, cell therapy, SNAP-CAR, CD38-GEAR-NK, CD38-Diagnostic